These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

163 related items for PubMed ID: 8280690

  • 1. Macrophages in proliferative vitreoretinopathy and proliferative diabetic retinopathy: differentiation of subpopulations.
    Esser P, Heimann K, Wiedemann P.
    Br J Ophthalmol; 1993 Nov; 77(11):731-3. PubMed ID: 8280690
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Soluble TNF receptors in vitreoretinal proliferative disease.
    Limb GA, Hollifield RD, Webster L, Charteris DG, Chignell AH.
    Invest Ophthalmol Vis Sci; 2001 Jun; 42(7):1586-91. PubMed ID: 11381065
    [Abstract] [Full Text] [Related]

  • 5. Indicators of oxidative tissue damage and inflammatory activity in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
    Augustin AJ, Spitznas M, Koch F, Grus F, Böker T.
    Ger J Ophthalmol; 1995 Jan; 4(1):47-51. PubMed ID: 7728110
    [Abstract] [Full Text] [Related]

  • 6. Apoptosis and cell proliferation in proliferative retinal disorders: PCNA, Ki-67, caspase-3, and PARP expression.
    Zhang X, Barile G, Chang S, Hays A, Pachydaki S, Schiff W, Sparrow J.
    Curr Eye Res; 2005 May; 30(5):395-403. PubMed ID: 16020270
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Tenascin and decorin in epiretinal membranes of proliferative vitreoretinopathy and proliferative diabetic retinopathy.
    Hagedorn M, Esser P, Wiedemann P, Heimann K.
    Ger J Ophthalmol; 1993 Feb; 2(1):28-31. PubMed ID: 7679595
    [Abstract] [Full Text] [Related]

  • 9. Intercellular adhesion molecule-1 levels in plasma and vitreous from patients with vitreoretinal disorders.
    Esser P, Bresgen M, Fischbach R, Heimann K, Wiedemann P.
    Ger J Ophthalmol; 1995 Sep; 4(5):269-74. PubMed ID: 7496336
    [Abstract] [Full Text] [Related]

  • 10. [Idiopathic proliferative vitreoretinopathy. Activation of microglial cells as the deciding factor].
    Weller M, Esser P, Heimann K, Wiedemann P.
    Ophthalmologe; 1992 Oct; 89(5):387-90. PubMed ID: 1304218
    [Abstract] [Full Text] [Related]

  • 11. Upregulation of RAGE and its ligands in proliferative retinal disease.
    Pachydaki SI, Tari SR, Lee SE, Ma W, Tseng JJ, Sosunov AA, Cataldergirmen G, Scarmeas N, Caspersen C, Chang S, Schiff WM, Schmidt AM, Barile GR.
    Exp Eye Res; 2006 May; 82(5):807-15. PubMed ID: 16364297
    [Abstract] [Full Text] [Related]

  • 12. Proliferative activity in epiretinal membranes. The use of the monoclonal antibody Ki-67 in proliferative vitreoretinal diseases.
    Heidenkummer HP, Kampik A, Petrovski B.
    Retina; 1992 May; 12(1):52-8. PubMed ID: 1565872
    [Abstract] [Full Text] [Related]

  • 13. [Thrombospondin and its importance in proliferative retinal diseases].
    Esser P, Weller M, Heimann K, Wiedemann P.
    Fortschr Ophthalmol; 1991 May; 88(4):337-40. PubMed ID: 1786916
    [Abstract] [Full Text] [Related]

  • 14. Detection of vascular endothelial growth factor and tumor necrosis factor alpha in epiretinal membranes of proliferative diabetic retinopathy, proliferative vitreoretinopathy and macular pucker.
    Armstrong D, Augustin AJ, Spengler R, Al-Jada A, Nickola T, Grus F, Koch F.
    Ophthalmologica; 1998 May; 212(6):410-4. PubMed ID: 9787233
    [Abstract] [Full Text] [Related]

  • 15. Apoptosis in proliferative vitreoretinal disorders: possible involvement of TGF-beta-induced RPE cell apoptosis.
    Esser P, Heimann K, Bartz-schmidt KU, Fontana A, Schraermeyer U, Thumann G, Weller M.
    Exp Eye Res; 1997 Sep; 65(3):365-78. PubMed ID: 9299173
    [Abstract] [Full Text] [Related]

  • 16. Interleukin-8, nitric oxide and glutathione status in proliferative vitreoretinopathy and proliferative diabetic retinopathy.
    Cicik E, Tekin H, Akar S, Ekmekçi OB, Donma O, Koldaş L, Ozkan S.
    Ophthalmic Res; 2003 Sep; 35(5):251-5. PubMed ID: 12920337
    [Abstract] [Full Text] [Related]

  • 17. [Macrophages and HLA-DR expression in proliferative vitreoretinopathy].
    Scheiffarth OF, Tang S, Kampik A.
    Fortschr Ophthalmol; 1990 Sep; 87(4):340-3. PubMed ID: 2210559
    [Abstract] [Full Text] [Related]

  • 18. Macrophage-Myofibroblast Transition Contributes to Myofibroblast Formation in Proliferative Vitreoretinal Disorders.
    Abu El-Asrar AM, De Hertogh G, Allegaert E, Nawaz MI, Abouelasrar Salama S, Gikandi PW, Opdenakker G, Struyf S.
    Int J Mol Sci; 2023 Aug 31; 24(17):. PubMed ID: 37686317
    [Abstract] [Full Text] [Related]

  • 19. [Detection of coagulation factor XIII in the vitreous body and periretinal membranes in proliferative retinal diseases].
    Bresgen M, Weller M, Heimann K, Wiedemann P.
    Fortschr Ophthalmol; 1990 Aug 31; 87(3):279-82. PubMed ID: 2198204
    [Abstract] [Full Text] [Related]

  • 20. Immunolocalization of integrins in proliferative retinal membranes.
    Robbins SG, Brem RB, Wilson DJ, O'Rourke LM, Robertson JE, Westra I, Planck SR, Rosenbaum JT.
    Invest Ophthalmol Vis Sci; 1994 Aug 31; 35(9):3475-85. PubMed ID: 8056523
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.